Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations.
Galluzzo M, Chiricozzi A, Cinotti E, Brunasso G, Congedo M, Esposito M, Franchi C, Malara G, Narcisi A, Piaserico S, Tiberio R, Argenziano G, Fabbrocini G, Parodi A.
Galluzzo M, et al. Among authors: congedo m.
Expert Opin Biol Ther. 2022 Mar;22(3):367-376. doi: 10.1080/14712598.2022.1988566. Epub 2021 Oct 12.
Expert Opin Biol Ther. 2022.
PMID: 34607513
Free article.